New drug tested for Tough-to-Treat skin cancer
NCT ID NCT07047885
Summary
This early-stage study is testing a medication called ropeginterferon for people with advanced cutaneous T-cell lymphoma (CTCL), a type of skin cancer. The main goals are to find the safest and most effective dose and to see how well the drug works in patients whose disease hasn't responded adequately to previous skin-focused treatments. The study will enroll about 38 adults who have tried at least two prior therapies without sufficient success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.